 BOCA RATON, Fla., Aug. 17, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. AzurRx or the Company NASDAQ: AZRX, a company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today announced the World Health Organization WHO has published adrulipase alfa as the proposed International Nonproprietary Name INN for MS1819. MS1819 is a recombinant lipase enzyme that is currently under development for the treatment of exocrine pancreatic insufficiency EPI associated with cystic fibrosis and chronic pancreatitis. 